Literature DB >> 16595073

Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: potential breast cancer risk alleles and their distribution across human populations.

Sevtap Savas1, Steffen Schmidt, Hamdi Jarjanazi, Hilmi Ozcelik.   

Abstract

Although highly penetrant alleles of BRCA1 and BRCA2 have been shown to predispose to breast cancer, the majority of breast cancer cases are assumed to result from the presence of low-moderate penetrant alleles and environmental carcinogens. Non-synonymous single nucleotide polymorphisms (nsSNPs) are hypothesised to contribute to disease susceptibility and approximately 30 per cent of them are predicted to have a biological significance. In this study, we have applied a bioinformatics-based strategy to identify breast cancer-related nsSNPs from 981 carcinogenesis-related genes expressed in breast tissue. Our results revealed a total of 367 validated nsSNPs, 109 (29.7 per cent) of which are predicted to affect the protein function (functional nsSNPs), suggesting that these nsSNPs are likely to influence the development and homeostasis of breast tissue and hence contribute to breast cancer susceptibility. Sixty-seven of the functional nsSNPs presented as commonly occurring nsSNPs (minor allele frequencies > or =5 per cent), representing excellent candidates for breast cancer susceptibility. Additionally, a non-uniform distribution of the common functional nsSNPs among different human populations was observed: 15 nsSNPs were reported to be present in all populations analysed, whereas another set of 15 nsSNPs was specific to particular population(s). We propose that the nsSNPs analysed in this study constitute a unique resource of potential genetic factors for breast cancer susceptibility. Furthermore, the variations in functional nsSNP allele frequencies across major population backgrounds may point to the potential variability of the molecular basis of breast cancer predisposition and treatment response among different human populations.

Entities:  

Mesh:

Year:  2006        PMID: 16595073      PMCID: PMC3500178          DOI: 10.1186/1479-7364-2-5-287

Source DB:  PubMed          Journal:  Hum Genomics        ISSN: 1473-9542            Impact factor:   4.639


Introduction

Mutations of BRCA1[1] and BRCA2[2] confer high breast cancer risk to the carriers. Such highly penetrant mutations are only responsible for a small fraction (~5-10 per cent) of all breast cancer cases,[3,4] however, suggesting the presence of other, yet to be identified, mutations in other breast cancer predisposition genes [5-7]. Mutations in a number of genes, such as p53,[8]ATM[6] and Chek2,[9] have also been shown to contribute to breast cancer risk in a very small fraction of breast cancer cases. So far, no other high-penetrant breast cancer susceptibility gene has been identified; however, genetic variations including single nucleotide polymorphisms (SNPs) have been hypothesised to act as low-moderate penetrant alleles and contribute to breast cancer, as well as other complex diseases [7,10-12]. Variations in protein sequence and function are mainly due to the non-synonymous form of SNPs (nsSNPs). The fraction of nsSNPs in the genome is relatively low (~10 per cent of all coding SNPs)[13] compared with other types, but they are more likely to alter the structure, function and interaction of the proteins, and thus constitute a set of candidate genetic factors associated with disease predisposition [14,15]. Approximately 30 per cent of the nsSNPs are predicted to have biological consequences [16-18]. Several nsSNPs from the proteins acting in a variety of cellular pathways--such as apoptosis,[19] oxidative stress[20] and signal transduction[21]--have already been reported to be associated with an increased/decreased risk of breast cancer. Several studies have described cancer-relevant nsSNPs;[22-25] however, to our knowledge they have not been studied in the context of expression of genes in a particular tissue. Clearly, in order for genes to be linked to a disease of a tissue, their protein products should somehow influence that particular tissue, either as exogenous proteins (such as hormones) or endogenous proteins (such as the proteins expressed in that tissue) [26,27]. In this study, we have applied a bioinformatics-based strategy and identified potentially functional nsSNPs from endogenous carcinogenesis-related proteins expressed in breast tissue.

Methods

Genes

The Ensembl transcript identifiers (http://www.ensembl.org/)[28] of the genes expressed in breast tissue were retrieved from the TissueInfo database (db) (http://icb.med.cornell.edu/services/tissueinfo/query) [29]. The list of carcinogenesis-related genes from 18 different categories ('DNA adduct', 'DNA damage', 'DNA replication', 'angiogenesis', 'apoptosis', 'behavior', 'cell cycle', 'cell signaling', 'development', 'gene regulation', 'transcription', 'immunology', 'metabolism', 'metastasis', 'pharmacology', 'signal transduction', 'tumor suppressors/oncogenes' and 'miscellaneous') was retrieved from the National Cancer Institute's Cancer Genome Anatomy Project Genetic Annotation Initiative ([CGAP-GAI] website [http://lpgws.nci.nih.gov/html-cgap/cgl/]) [30]. The genes retrieved from the TissueInfo and the CGAP-GAI resources were then cross-referenced with each other to identify the group of carcinogenesis-related genes that are expressed in breast tissue.

nsSNPs

The nsSNPs from the group of carcinogenesis-related genes expressed in breast tissue were retrieved from dbSNP build 120 (http://www.ncbi.nlm.nih.gov/SNP/) [31]. Only the nsSNPs detected in ≥ 2 chromosomes in a sample panel of ≥ 40 chromosomes were included in this study (validated nsSNPs). Seventeen nsSNPs were found in both less and more than 5 per cent of the chromosomes analysed in different sample sets; for simplicity, we have classified such nsSNPs within the nsSNP set with ≥ 5 per cent minor allele frequencies throughout this paper.

PolyPhen analysis

The PolyPhen predictions[18] were retrieved from a pre-computed dbSNP-PolyPhen resource. All PolyPhen predictions were based on either alignment of at least five similar proteins (for a more reliable prediction) or structural parameters.

Results

The results obtained in this study are summarised in Table 1 and constitute only the validated nsSNPs with a reliable prediction made by the PolyPhen prediction tool (see Methods). A total of 367 nsSNPs from 189 carcinogenesis-related genes expressed in breast tissue are presented. A total of 109 nsSNPs (28.4 per cent) from 75 genes were predicted potentially to affect the protein function (functional nsSNPs). Additionally, 61.5 per cent (n = 67) of the potentially functional nsSNPs represented commonly occurring nsSNPs in the population (≥ 5 per cent minor allele frequency; Table 2). In this paper, we mainly discuss the commonly occurring functional nsSNPs; however, the list of rarely occurring functional nsSNPs can also be found under the supplementary table (http://www.ozceliklab.com/Breast_rare_nsSNPs/).
Table 1

Summary of the results.

n
Genes

 Carcinogenesis-related genes2,832

  Expressed in breast tissue981

   With validated nsSNPs189

   With functional nsSNPs75

nsSNPs

 Validated nsSNPs367

  Benign by PolyPhen258

  Functional by PolyPhen109

   With ≥ 5% minor allele frequency67

   With < 5% minor allele frequency42

Abbreviation: n = number; nsSNP = non-synonymous form of single nucleotide polymorphisms. Please note that only the genes and the nsSNPs for which a reliable PolyPhen prediction (based on ≥ 5 proteins in the alignment) was available are shown in this table.

Table 2

Functional and common non-synonymous form of single nucleotide polymorphisms (nsSNPs) from the breast tissue-expressed carcinogenesis-related genes.

GeneaAccessionnumberSNP IDbAmino acidchangecCodondDamagingalleleDamagingamino acidePolyPhenpredictionPathwayf
ACY1NM_000666.1rs2229152R386Ccgt/tgttCProbably damagingIM

ADD1NM_014189.2rs4961G460Wggg/tggtWProbably damagingIM

ADD1NM_014189.2rs4962N541Iaat/atttIProbably damagingIM

ADD1NM_014189.2rs4971Y270Ntat/aataNProbably damagingIM

ADMNM_001124.1rs5005S50Ragc/agggRPossibly damagingAN

ADRB2NM_000024.3rs1042713G16Rgga/agaaRPossibly damagingBE, IM

ALDH2NM_000690.2rs671E504Kgaa/aaaaKPossibly damagingIM, PH

APOENM_000041.1rs429358C130Rtgc/cgccRProbably damagingIM

AXIN2NM_004655.1rs2240308P50Scct/tcttSProbably damagingDE

C2NM_000063.3rs4151648R734Ccgc/tgctCPossibly damagingIM

CD2NM_001767.2rs699738H266Qcac/caaaQProbably damagingAN, IM, MET

CDH12NM_004061.2rs4371716V68Mgtg/atggVProbably damagingIM

CHGANM_001275.2rs729940R399Wcgg/tggtWProbably damagingIM

CHGANM_001275.2rs9658667G382Sggc/agcaSPossibly damagingIM

CLUNM_001831.1rs9331936N317Haac/caccHPossibly damagingIM

CSF1NM_000757.3rs2229165G438Rggg/aggaRProbably damagingIM

CSF3RNM_000760.2rs3917973M231Tatg/acgcTProbably damagingIM

CSF3RNM_000760.2rs3917974Q346Rcag/cgggRPossibly damagingIM

CSF3RNM_000760.2rs3917991D510Hgac/caccHPossibly damagingIM

CYBANM_000101.1rs4673Y72Htac/caccHPossibly damagingIM

CYP11B1NM_000497.2rs4541A386Vgcg/gtgcAPossibly damagingPH

CYP11B1NM_000497.2rs5287M160Iatg/atccIPossibly damagingPH

CYP11B1NM_000497.2rs5294Y439Htac/cactYProbably damagingPH

CYP11B1NM_000497.2rs5312E383Vgag/gtgtVProbably damagingPH

CYP1B1NM_000104.2rs1800440N453Saac/agcgSPossibly damagingIM, PH

CYP2A6NM_000762.4rs1801272L160Hctc/cacaHProbably damagingIM, PH

CYP2B6NM_000767.3rs2279343K262Raag/aggaKPossibly damagingPH

CYP2C9NM_000771.2rs1799853R144Ccgt/tgttCProbably damagingIM, PH

DAG1NM_004393.1rs2131107S14Wtcg/tggcSProbably damagingIM

ENGNM_000118.1rs1800956D366Hgac/caccHPossibly damagingAN, DE, IM, MET

EPHX1NM_000120.2rs1051740Y113Htac/caccHPossibly damagingIM, ME, PH

ERBB2NM_004448.1rs1058808P1170Accc/gccgAPossibly damagingIM, ST, TS/ON

F2RNM_001992.2rs2230849Y187Ntac/aacaNProbably damagingIM

FPR1NM_002029.3rs867228E346Agag/gcgcAPossibly damagingIM

FUCA2NM_032020.3rs3762001H371Ycat/tattYPossibly damagingIM

GAANM_000152.2rs1800307G576Sggc/agcaSPossibly damagingIM

GBP1NM_002053.1rs1048425T349Sacc/agcgSPossibly damagingCS

GYS1NM_002103.3rs5453P691Acca/gcagAProbably damagingIM

GYS1NM_002103.3rs5456K130Eaag/gaggEPossibly damagingIM

GYS1NM_002103.3rs5461N283Saat/agtgSPossibly damagingIM

HK2NM_000189.4rs2229629R844Kagg/aaggRPossibly damagingIM, MIS

LIG4NM_002312.2rs1805388T9Iact/atttIPossibly damagingDA, DD

MC1RNM_002386.2rs1805005V60Lgtg/ttgtLPossibly damagingIM

MC1RNM_002386.2rs1805007R151Ccgc/tgctCProbably damagingIM

MC1RNM_002386.2rs3212366F196Lttc/ctccLProbably damagingIM

MMP9NM_004994.1rs2250889R574Pcgg/ccggRPossibly damagingAN, IM

MMP9NM_004994.1rs3918252N127Kaac/aaggKProbably damagingAN, IM

MNDANM_002432.1rs2276403H357Ycac/tactYPossibly damagingGR, TR

MUC4NM_004532.2rs2259292G88Dggc/gacgGPossibly damagingIM

NFATC1NM_006162.3rs754093C751Gtgt/ggtgGProbably damagingIM

NOTCH4NM_004557.2rs2071282P203Lccc/ctctLProbably damagingIM, TS/ON

PGM3NM_015599.1rs473267D466Ngat/aataNPossibly damagingIM

PLAUNM_002658.1rs2227564L141Pctg/ccgtLPossibly damagingAN

PLAURNM_002659.1rs4760L317Pctc/ccccPPossibly damagingAN

PTGS2NM_000963.1rs5272E488Ggag/ggggGProbably damagingIM, MIS

PTPN3NM_002829.2rs3793524A90Pgcc/cccgAProbably damagingCC, CS

SLC1A5NM_005628.1rs3027956P17Accc/gccgAPossibly damagingIM

STAT2NM_005419.2rs2066816Q66Hcag/cattHPossibly damagingIM, ST

TBXAS1NM_001061.2rs5760G390Vggc/gtctVProbably damagingIM

TBXAS1NM_001061.2rs5762R425Ccgc/tgctCProbably damagingIM

TBXAS1NM_001061.2rs5770R261Gagg/ggggGProbably damagingIM

TDGNM_003211.2rs4135113G199Sggc/agcaSPossibly damagingDD

TUBA1NM_006000.1rs3731891R243Ccgc/tgctCProbably damagingCS, MET

TYRNM_000372.2rs1042602S192Ytct/tataYPossibly damagingME

VCAM1NM_001078.2rs3783613G413Aggt/gctcAPossibly damagingAN, CS, IM, MET

XRCC1NM_006297.1rs25489R280Hcgt/cataHPossibly damagingDD, DR, IM

XRCC1NM_006297.1rs1799782R194Wcgg/tggtWProbably damagingDD, DR, IM

Abbreviations: AN = angiogenesis; BE = behaviour, CC = cell cycle; CS = cell signalling; DA = DNA adduct; DD = DNA damage; DE = development; GR = gene regulation; IM = immunology; ME = metabolism;

MET = metastasis; MIS = miscellaneous; PH = pharmacology; ST = signal transduction; TS/ON = tumour suppressor/oncogene; TR = transcription.

All nsSNPs are with ≥ 5 per cent minor allele frequency.

The gene symbols are as approved by the HUGO Gene Nomenclature Committee [67].

SNP identifiers (IDs) correspond to the dbSNP IDs (http://www.ncbi.nlm.nih.gov/SNP/) [31].

The position of the amino acid substitution and the amino acids specified by the major and minor SNP alleles are indicated.

The codons specified by the major and the minor SNP alleles are shown. The nucleotide change is underlined.

One-letter codes for the amino acids that are predicted to affect the protein function by PolyPhen.

The pathway(s) that the proteins are implicated in are as shown by the Cancer Genome Anatomy Project Genetic Annotation Initiative website (http://lpgws.nci.nih.gov/html-cgap/cgl/) [30].

Summary of the results. Abbreviation: n = number; nsSNP = non-synonymous form of single nucleotide polymorphisms. Please note that only the genes and the nsSNPs for which a reliable PolyPhen prediction (based on ≥ 5 proteins in the alignment) was available are shown in this table. Functional and common non-synonymous form of single nucleotide polymorphisms (nsSNPs) from the breast tissue-expressed carcinogenesis-related genes. Abbreviations: AN = angiogenesis; BE = behaviour, CC = cell cycle; CS = cell signalling; DA = DNA adduct; DD = DNA damage; DE = development; GR = gene regulation; IM = immunology; ME = metabolism; MET = metastasis; MIS = miscellaneous; PH = pharmacology; ST = signal transduction; TS/ON = tumour suppressor/oncogene; TR = transcription. All nsSNPs are with ≥ 5 per cent minor allele frequency. The gene symbols are as approved by the HUGO Gene Nomenclature Committee [67]. SNP identifiers (IDs) correspond to the dbSNP IDs (http://www.ncbi.nlm.nih.gov/SNP/) [31]. The position of the amino acid substitution and the amino acids specified by the major and minor SNP alleles are indicated. The codons specified by the major and the minor SNP alleles are shown. The nucleotide change is underlined. One-letter codes for the amino acids that are predicted to affect the protein function by PolyPhen. The pathway(s) that the proteins are implicated in are as shown by the Cancer Genome Anatomy Project Genetic Annotation Initiative website (http://lpgws.nci.nih.gov/html-cgap/cgl/) [30]. A fraction of protein products of genes bearing commonly occurring functional nsSNPs were found to be involved in one or more carcinogenesis-related biological pathways compiled by the CGAP-GAI[30] (Table 2). Such nsSNPs were mostly found in the proteins from DNA repair (three genes, four nsSNPs); metastasis (four genes, four nsSNPs); angiogenesis (seven genes, eight nsSNPs); pharmacology (seven genes, ten nsSNPs); and immunology (38 genes, 51 nsSNPs). We have also analysed the distribution of the commonly occurring functional nsSNPs across human populations. For simplicity, we have categorised the frequency information obtained from different dbSNP entries into three major groups: African (African and African-American), Caucasian (Caucasian and European) and Asian (Chinese and East Asian) populations. Minor allele frequencies for nsSNPs were available for at least three different human populations for 30 out of 67 commonly occurring functional nsSNPs (Table 3). Fifteen nsSNPs were found in all populations analysed (n ≥ 3). In the case of the remaining 15 nsSNPs, five were found exclusively in one population (ADM-S50R and MMP9-N127K in African; ALDH2-E504K and MNDA-H357Y in Asian; MC1R-R151C in Caucasian). Additionally, three nsSNPs were found in Caucasian, Asian or Hispanic samples, but not in the African samples (CHGA-G382S, CYP1B1-N453S and CYP2C9-R144C). Moreover, in the case of five nsSNPs, the major and the minor alleles were different among the populations analysed (ADBR2-G16R, CDH12-V68M, ERBB2-P1170A, PGM3-D466N and SLC1A5-P17A).
Table 3

Functional and common non-synonymous form of single nucleotide polymorphisms (nsSNPs) with frequency information available from different human populations.

Genea SNP IDb Amino acid change cAfricanAsianCaucasianHispanic
ADD1 rs4961G460W46 chr. G = 0.891 T = 0.10948 chr. G = 0.521 T = 0.47948 chr. G = 0.833 T = 0.167n/a

ADM rs5005S50R46 chr. C = 0.957 G = 0.04348 chr. C = 1.00048 chr. C = 1.000n/a

ADRB2 rs1042713G16R46 chr. G = 0.609 A = 0.39148 chr. A = 0.583 G = 0.41746 chr. G = 0.674 A = 0.326n/a

ALDH2 rs671E504K48 chr. G = 1.00048 0 G = 0.771 A = 0.22958 chr. G = 1.00044 chr. G = 1.000

CDH12 rs4371716V68M46 chr. T = 0.674 C = 0.32648 chr. C = 0.812 T = 0.18848 chr. C = 0.729 T = 0.271n/a

CHGA rs729940R399W114 chr. C = 0.954 T = 0.04688 chr. C = 0.715 T = 0.285104 chr. C = 0.893 T = 0.10756 chr. C = 0.769 T = 0.231

CHGA rs9658667G382S114 chr. G = 1.00088 chr. G = 0.982 A = 0.018104 chr. G = 0.951 A = 0.04956 chr. G = 0.941 A = 0.059

CSF3R rs3917973M231T48 chr. T = 0.938 C = 0.06248 chr. T = 1.00058 chr. T = 0.983 C = 0.01746 chr. T = 1.000

CSF3R rs3917991D510H48 chr. G = 0.750 C = 0.25048 chr. G = 1.00058 chr. G = 1.00046 chr. G = 0.935 C = 0.065

CYBA rs4673Y72H48 chr. C = 0.542 T = 0.4581480 chr. G = 0.907 A = 0.09360 chr. C = 0.683 T = 0.31746 chr. C = 0.783 T = 0.217

CYP1B1 rs1800440N453S48 chr. A = 1.00048 chr. A = 0.958 G = 0.04262 chr. A = 0.806 G = 0.19446 chr. A = 0.761 G = 0.239

CYP2A6 rs1801272L160H46 chr. T = 1.00046 chr. T = 1.00060 chr. T = 0.900 A = 0.10046 chr. T = 0.978 A = 0.022

CYP2C9 rs1799853R144C48 chr. C = 1.00048 chr. C = 0.979 T = 0.02162 chr. C = 0.871 T = 0.12946 chr. C = 0.935 T = 0.065

ENG rs1800956D366H46 chr. C = 0.978 G = 0.0221480 chr. C = 0.942 G = 0.05846 chr. C = 1.000n/a

EPHX1 rs1051740Y113H48 chr. T = 0.917C = 0.08384 chr. T = 0.620C = 0.38062 chr. T = 0.613C = 0.38746 chr. T = 0.587C = 0.413

ERBB2 rs1058808P1170A40 chr. C = 0.775 G = 0.2251502 chr. G = 0.514 C = 0.48648 chr. G = 0.646 C = 0.354n/a

FPR1 rs867228E346A44 chr. G = 0.818 T = 0.18246 chr. G = 0.761 T = 0.23948 chr. G = 0.771 T = 0.229n/a

FUCA2 rs3762001H371Y44 chr. G = 0.818 A = 0.1821282 chr. G = 0.789 A = 0.21144 chr. G = 0.795 A = 0.205n/a

LIG4 rs1805388T9I48 chr. C = 0.979T = 0.02148 chr. G = 0.792A = 0.20862 chr. C = 0.871T = 0.12946 chr.C = 0.848T = 0.152

MC1R rs1805007R151C42 chr. C = 1.00040 chr. C = 1.00046 chr. C = 0.891 T = 0.109n/a

MMP9 rs2250889R574P46 chr. C = 0.870 G = 0.1301488 chr. C = 0.688 G = 0.31248 chr. C = 0.896 G = 0.104n/a

MMP9 rs3918252N127K48 chr. C = 0.938 G = 0.06248 chr. C = 1.00048 chr. C = 1.000n/a

MNDA rs2276403H357Y46 chr. C = 1.0001484 chr. C = 0.944 T = 0.05648 chr. C = 1.000n/a

PGM3 rs473267D466N46 chr. T = 0.565 C = 0.43584 chr. C = 0.750 T = 0.25048 chr. C = 0.688 T = 0.312n/a

PLAU rs2227564L141P48 chr. C = 0.979 T = 0.0211492 chr. G = 0.783 A = 0.21744 chr. C = 0.659 T = 0.341n/a

PTPN3 rs3793524A90P46 chr. G = 0.522 C = 0.4781498 chr. G = 0.628 C = 0.37246 chr. C = 0.717 G = 0.283n/a

SLC1A5 rs3027956P17A46 chr. G = 0.957 C = 0.04342 chr. G = 0.524 C = 0.476146 chr. C = 0.710 G = 0.290n/a

TYR rs1042602S192Y46 chr. C = 0.957 A = 0.04348 chr. C = 1.00048 chr. C = 0.750 A = 0.250n/a

VCAM1 rs3783613G413A48 chr. G = 0.938 C = 0.06244 chr. G = 0.977 C = 0.02348 chr. G = 1.000n/a

XRCC1 rs25489R280H48 chr. G = 0.937A = 0.06384 chr. C = 1.00062 chr. G = 0.968A = 0.03246 chr.G = 0.957A = 0.043

Abbreviations: chr: chromosomes; n/a: not available.

The gene symbols are as approved by the HUGO Gene Nomenclature Committee [67].

SNP identifiers (IDs) correspond to the dbSNP IDs (http://www.ncbi.nlm.nih.gov/SNP/) [31].

The position of the amino acid substitution and the amino acids specified by the major and minor SNP alleles are indicated. The frequency information is as in dbSNP build 123 and is based on ≥ 40 chromosomes. Please note that the samples annotated as African and African-American; Caucasian and European; Chinese and East Asian are combined together here and are referred to as African, Caucasian and Asian, respectively. Whenever more than one entry was available for a group, only the information from the entries with the highest number of chromosomes is included here.

Functional and common non-synonymous form of single nucleotide polymorphisms (nsSNPs) with frequency information available from different human populations. Abbreviations: chr: chromosomes; n/a: not available. The gene symbols are as approved by the HUGO Gene Nomenclature Committee [67]. SNP identifiers (IDs) correspond to the dbSNP IDs (http://www.ncbi.nlm.nih.gov/SNP/) [31]. The position of the amino acid substitution and the amino acids specified by the major and minor SNP alleles are indicated. The frequency information is as in dbSNP build 123 and is based on ≥ 40 chromosomes. Please note that the samples annotated as African and African-American; Caucasian and European; Chinese and East Asian are combined together here and are referred to as African, Caucasian and Asian, respectively. Whenever more than one entry was available for a group, only the information from the entries with the highest number of chromosomes is included here.

Discussion

A portion of SNPs is considered to contribute to complex disease development [7,10-12]. SNPs in or around the candidate genes might be directly linked to a disease; however, not all SNPs are supposed to affect gene expression and function, so selection of those with potential effects is keenly debated [32]. Several studies have developed tools and/or systematically analysed nsSNPs to identify those that affect gene function based on evolutionary conservation or structural parameters [16-18,33]. PolyPhen[18] is one such web-based tool utilised to select the nsSNPs that are likely to affect protein function. In short, the PolyPhen predictions are based on protein alignments, structural parameters or sequence annotations. The sensitivity of PolyPhen has been reported to be approximately 82 per cent [18]. In this study, we hypothesised that the systematic analysis of candidate genes that are expressed in the affected tissue is likely to improve and enrich the identification of disease-susceptibility alleles. Accordingly, using a bioinformatics-based strategy, we identified the functional nsSNPs from a large number of genes related to the carcinogenesis-related pathways (DNA repair, cell cycle, signal transduction, etc), which are expressed in breast tissue. We propose that these potentially functional nsSNPs can result in abnormalities at the protein level, which are likely to affect the development, metabolism and homeostasis of the breast tissue, and thus can contribute to breast cancer susceptibility. The genes with functional nsSNPs identified in this study were from a variety of carcinogenesis-related cellular pathways. According to this information, possible biological roles for these nsSNPs may be suggested. For example, nsSNPs from angiogenesis- and metastasis-related proteins may have roles in tumour growth and the development of metastatic tumours [34,35]. Additionally, DNA repair nsSNPs may lead to the accumulation of somatic mutations and thus can participate in cancer initiation and promotion [34-36]. Furthermore, together with the DNA repair nsSNPs, the nsSNPs from the pharmacology genes may also be good candidates for the studies targeting the efficacy, differential response and adverse effect of chemo-/radiotherapy in breast cancer [37-39]. The majority of the nsSNPs were from the genes related to immunological responses (74.6 per cent), which can both suppress and promote tumorigenesis [34]. It is likely that the larger number of the functional nsSNPs in immune system-related genes is a reflection of the large number of immunology genes in the breast tissue-expressed gene set (60 per cent). A considerable number of genes with functional nsSNPs have been previously linked to breast cancer aetiology: ADM,[40]ADRB2,[41]APOE,[42]CHGA,[43]CSF1,[44]CYP1B1,[45]DAG1,[46]ENG,[47]EPHX1,[48]ERBB2,[49]F2R,[50]MMP9,[51]MUC4,[52]NFATC1,[53]NOTCH4,[54]PLAU,[55]PLAUR,[55]PTGS2[56] and VCAM1 [57]. Therefore, we propose that the nsSNPs in Table 2 are excellent candidates as genetic factors involved in breast cancer initiation, promotion or progression. Additionally, some of these nsSNPs may be critical for breast cancer treatment outcome. When the distribution of the commonly occurring functional nsSNPs was analysed, differences in the major alleles and the allele frequencies across human populations were observed. For example, 15 commonly occurring nsSNPs were found in all populations, whereas another set of 15 nsSNPs was specific to particular population(s). These differences might be reflections of either the age of the allele, founder effects or the dissimilar selective pressures acting on different populations [58,59]. Most importantly, the data also indicate that a common nsSNP with a potential biological consequence in our set was equally likely to be either prevalent across different human populations or limited to some populations. Clearly, the latter prompted us to conclude that the population-specific functional nsSNPs may contribute to the genetic predisposition in individuals with a specific background. In this regard, this conclusion is consistent with previous studies in which genetic variations with significantly different allelic frequencies among populations were found to be associated with specific disease or differential drug responses [60-65]. This information may be particularly helpful to researchers in determining which nsSNPs may be relevant to utilise in specific population-based studies. In addition, although further analyses are required, it is tempting to speculate that these nsSNPs may be a part of the potential variability of the molecular basis of breast cancer predisposition and drug response among different human populations. Data integration from several databases forms the basis of our strategy to determine functional SNPs of breast tissue-expressed genes. The quality and the quantity of the genomic data within individual databases influence the comprehensiveness of the combined data. The functional SNP list presented in this study is a result of data integration from three databases -- namely, TissueInfo,[29] Ensembl,[28] and dbSNP [31]. The non-matching data fields (eg transcript identifiers) between TissueInfo, Ensembl and dbSNP have been the main source of missing data. For example, although BRCA1 was known to have a potentially functional SNP (predicted previously), this information has not been captured because of non-matching transcript identifier information for BRCA1 in the databases. Thus, incompatibility of data in different databases has been a rate-limiting factor for the bioinformatics-based strategies presented here. The improvement of the quality and the quantity of genomic data in the databases will prove beneficial for researching complex questions. Also, the genes presented in this paper are based on the expressed sequence tag information, which may lead to an under-representation of rarely expressed genes [29,66]. Data integration using other tissue expression databases is likely to enrich the quality of the data produced. Nevertheless, although it is possible that the SNPs presented here may not represent the most comprehensive list, the SNPs identified using the proposed strategy represent a valuable resource for studying the genetic predisposition to breast cancer.

Conclusion

In conclusion, we have designed a novel strategy to identify potentially functional variants of cancer-related genes expressed in breast tissue. Our results demonstrated the presence of 109 nsSNPs with a potential biological consequence, 67 of which were frequent in human populations. We propose that, together with other genetic and environmental factors, these nsSNPs may be involved in breast cancer initiation and progression; thus, these nsSNPs represent the premium candidates as genetic variations of breast cancer predisposition. We also suggest that a considerable fraction of the nsSNPs may, in fact, be population-specific genetic variations.
  67 in total

Review 1.  Gene discovery in the auditory system using a tissue specific approach.

Authors:  Cynthia C Morton
Journal:  Am J Med Genet A       Date:  2004-09-15       Impact factor: 2.802

2.  Pattern of sequence variation across 213 environmental response genes.

Authors:  Robert J Livingston; Andrew von Niederhausern; Anil G Jegga; Dana C Crawford; Christopher S Carlson; Mark J Rieder; Sivakumar Gowrisankar; Bruce J Aronow; Robert B Weiss; Deborah A Nickerson
Journal:  Genome Res       Date:  2004-09-13       Impact factor: 9.043

3.  The future of genetic studies of complex human diseases.

Authors:  N Risch; K Merikangas
Journal:  Science       Date:  1996-09-13       Impact factor: 47.728

4.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

5.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

Review 6.  The search for low-penetrance cancer susceptibility alleles.

Authors:  Richard S Houlston; Julian Peto
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

Review 7.  Breast cancer genetics: unsolved questions and open perspectives in an expanding clinical practice.

Authors:  Shirley V Hodgson; Patrick J Morrison; Melita Irving
Journal:  Am J Med Genet C Semin Med Genet       Date:  2004-08-15       Impact factor: 3.908

Review 8.  Notch in mammary gland development and breast cancer.

Authors:  Katerina Politi; Nikki Feirt; Jan Kitajewski
Journal:  Semin Cancer Biol       Date:  2004-10       Impact factor: 15.707

9.  Chromogranin A and B gene expression in carcinomas of the breast. Correlation of immunocytochemical, immunoblot, and hybridization analyses.

Authors:  A Pagani; M Papotti; H Höfler; R Weiler; H Winkler; G Bussolati
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

10.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

View more
  7 in total

1.  Association analysis of rs1049255 and rs4673 transitions in p22phox gene with coronary artery disease: A case-control study and a computational analysis.

Authors:  M Mazaheri; M Karimian; M Behjati; F Raygan; A Hosseinzadeh Colagar
Journal:  Ir J Med Sci       Date:  2017-05-04       Impact factor: 1.568

2.  Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.

Authors:  Vitaly Balan; Pratima Nangia-Makker; Ann G Schwartz; Young Suk Jung; Larry Tait; Victor Hogan; Tirza Raz; Yi Wang; Zeng Quan Yang; Gen Sheng Wu; Yongjun Guo; Huixiang Li; Judith Abrams; Fergus J Couch; Wilma L Lingle; Ricardo V Lloyd; Stephen P Ethier; Michael A Tainsky; Avraham Raz
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 3.  Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health.

Authors:  Lorena Pochini; Mariafrancesca Scalise; Michele Galluccio; Cesare Indiveri
Journal:  Front Chem       Date:  2014-08-11       Impact factor: 5.221

4.  A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival.

Authors:  Jimmy Belotte; Nicole M Fletcher; Mohammed G Saed; Mohammed S Abusamaan; Gregory Dyson; Michael P Diamond; Ghassan M Saed
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

5.  Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.

Authors:  Dale L Bodian; Justine N McCutcheon; Prachi Kothiyal; Kathi C Huddleston; Ramaswamy K Iyer; Joseph G Vockley; John E Niederhuber
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

6.  Development of an AmpliSeqTM Panel for Next-Generation Sequencing of a Set of Genetic Predictors of Persisting Pain.

Authors:  Dario Kringel; Mari A Kaunisto; Catharina Lippmann; Eija Kalso; Jörn Lötsch
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

Review 7.  Role of Endoglin Insertion and rs1800956 Polymorphisms in Intracranial Aneurysm Susceptibility: A Meta-Analysis.

Authors:  Xin Hu; Yuan Fang; Yun-Ke Li; Wen-Ke Liu; Hao Li; Lu Ma; Chao You
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.